Literature DB >> 11704853

PML interaction with p53 and its role in apoptosis and replicative senescence.

M Pearson1, P G Pelicci.   

Abstract

A network of control pathways has been characterized that arrest growth or induce apoptosis in response to potentially tumorogenic events such as genotoxic stress or oncogene expression. Ablation, or functional disruption, of these pathways is frequently observed during multistep carcinogenesis. Analysis of those genes most commonly compromized in tumours has led to the identification of the transcription factor p53 and the E2F binding protein Retinoblastoma (Rb), as key regulators of these processes. This review discusses recent data, demonstrating that the Promyelocytic Leukemia (PML) protein can physically and functionally interact with both p53 and Rb, suggesting that PML may be a novel regulator of these pathways.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704853     DOI: 10.1038/sj.onc.1204856

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  36 in total

1.  Impairment of p53 acetylation, stability and function by an oncogenic transcription factor.

Authors:  Alessandra Insinga; Silvia Monestiroli; Simona Ronzoni; Roberta Carbone; Mark Pearson; Giancarlo Pruneri; Giuseppe Viale; Ettore Appella; PierGiuseppe Pelicci; Saverio Minucci
Journal:  EMBO J       Date:  2004-02-19       Impact factor: 11.598

Review 2.  Extracellular matrix, nuclear and chromatin structure, and gene expression in normal tissues and malignant tumors: a work in progress.

Authors:  Virginia A Spencer; Ren Xu; Mina J Bissell
Journal:  Adv Cancer Res       Date:  2007       Impact factor: 6.242

3.  The adenoviral E1B 55-kilodalton protein controls expression of immune response genes but not p53-dependent transcription.

Authors:  Daniel L Miller; Brenden Rickards; Michael Mashiba; Wenying Huang; S J Flint
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

Review 4.  Classification of ovarian cancer: a genomic analysis.

Authors:  Michael P Stany; Tomas Bonome; Fred Wamunyokoli; Kristen Zorn; Laurent Ozbun; Dong-Choon Park; Ke Hao; Jeff Boyd; Anil K Sood; David M Gershenson; Ross S Berkowitz; Samuel C Mok; Michael J Birrer
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

5.  PML: An emerging tumor suppressor and a target with therapeutic potential.

Authors:  Erin L Reineke; Hung-Ying Kao
Journal:  Cancer Ther       Date:  2009-09-01

Review 6.  PML nuclear bodies: assembly and oxidative stress-sensitive sumoylation.

Authors:  Umut Sahin; Hugues de Thé; Valérie Lallemand-Breitenbach
Journal:  Nucleus       Date:  2014       Impact factor: 4.197

7.  SnoN activates p53 directly to regulate aging and tumorigenesis.

Authors:  Deng Pan; Qingwei Zhu; Michael J Conboy; Irina M Conboy; Kunxin Luo
Journal:  Aging Cell       Date:  2012-08-27       Impact factor: 9.304

8.  Expression of promyelocytic leukemia protein increases during the differentiation of human neuroblastoma cells.

Authors:  Eunsil Yu; Eun Kyung Choi; Chong Jai Kim
Journal:  Virchows Arch       Date:  2003-02-11       Impact factor: 4.064

9.  Increased levels of a particular phosphatidylcholine species in senescent human dermal fibroblasts in vitro.

Authors:  Eiji Naru; Yasukazu Takanezawa; Misako Kobayashi; Yuko Misaki; Kazuhiko Kaji; Kumi Arakane
Journal:  Hum Cell       Date:  2008-08       Impact factor: 4.174

10.  The human promyelocytic leukemia protein is a tumor suppressor for murine skin carcinogenesis.

Authors:  Victoria M Virador; Rafael E Flores-Obando; Adam Berry; Rinal Patel; Julia Zakhari; Yu-Chien Lo; Kathryn Strain; Joanna Anders; Christophe Cataisson; Laura A Hansen; Stuart H Yuspa
Journal:  Mol Carcinog       Date:  2009-07       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.